RU2706706C1 - Пероральная осмотическая фармацевтическая композиция вилдаглиптина - Google Patents

Пероральная осмотическая фармацевтическая композиция вилдаглиптина Download PDF

Info

Publication number
RU2706706C1
RU2706706C1 RU2018120202A RU2018120202A RU2706706C1 RU 2706706 C1 RU2706706 C1 RU 2706706C1 RU 2018120202 A RU2018120202 A RU 2018120202A RU 2018120202 A RU2018120202 A RU 2018120202A RU 2706706 C1 RU2706706 C1 RU 2706706C1
Authority
RU
Russia
Prior art keywords
vildagliptin
salt
pharmaceutical composition
released
osmotic
Prior art date
Application number
RU2018120202A
Other languages
English (en)
Russian (ru)
Inventor
Мандар Мадхукар КОДГУЛ
Амит БАНСАЛ
Ганеш САНГЛ
Капилешвар СВАИН
Нитин САЙГАЛ
Санджай ГАИКВАД
Сунил Кумар АГАРВАЛ
Original Assignee
Вокхардт Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вокхардт Лимитед filed Critical Вокхардт Лимитед
Application granted granted Critical
Publication of RU2706706C1 publication Critical patent/RU2706706C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018120202A 2015-12-28 2016-12-23 Пероральная осмотическая фармацевтическая композиция вилдаглиптина RU2706706C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4891MU2015 2015-12-28
IN4891/MUM/2015 2015-12-28
PCT/IB2016/057975 WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Publications (1)

Publication Number Publication Date
RU2706706C1 true RU2706706C1 (ru) 2019-11-20

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018120202A RU2706706C1 (ru) 2015-12-28 2016-12-23 Пероральная осмотическая фармацевтическая композиция вилдаглиптина

Country Status (6)

Country Link
KR (1) KR20180092981A (pt)
BR (1) BR112018013195A2 (pt)
MX (1) MX2018007681A (pt)
PH (1) PH12018550075A1 (pt)
RU (1) RU2706706C1 (pt)
WO (1) WO2017115252A1 (pt)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537880A1 (en) * 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
RU2423124C2 (ru) * 2005-06-10 2011-07-10 Новартис Аг Состав с модифицированным высвобождением, содержащий 1-[(3-гидроксиадамант-1-иламино)ацетил]пирролидин-2(s)-карбонитрил

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
BRPI0616195A2 (pt) 2005-09-20 2011-06-14 Novartis Ag uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
EP2578208B1 (en) 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
CA2881726A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537880A1 (en) * 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
RU2423124C2 (ru) * 2005-06-10 2011-07-10 Новартис Аг Состав с модифицированным высвобождением, содержащий 1-[(3-гидроксиадамант-1-иламино)ацетил]пирролидин-2(s)-карбонитрил
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor

Also Published As

Publication number Publication date
WO2017115252A1 (en) 2017-07-06
MX2018007681A (es) 2018-11-14
KR20180092981A (ko) 2018-08-20
BR112018013195A2 (pt) 2018-12-11
PH12018550075A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
JP5653218B2 (ja) アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
RU2372894C2 (ru) Покрытая таблетка и способ ее получения
US8486453B2 (en) Controlled release compositions with reduced food effect
JP5837072B2 (ja) 水溶性抗酸化剤を使用する製剤
KR20070078625A (ko) 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
AU2010260373A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
TW201206447A (en) Pharmaceutical formulations
RU2016125229A (ru) Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
RU2672573C2 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
KR20120104523A (ko) 디펩티딜 펩티다제―４ 억제제와 피오글리타존의 조합물의 제약 조성물
HRP20000213A2 (en) Extended release formulation
WO2014170770A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
KR100774774B1 (ko) 메트포르민 서방성 제제 및 그 제조방법
CN110251473B (zh) 羟哌吡酮口服缓释制剂
RU2706706C1 (ru) Пероральная осмотическая фармацевтическая композиция вилдаглиптина
WO2003082261A1 (en) Extended release venlafaxine formulations
EP3033075A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
CN115989031A (zh) 用于抑制透析转化或肾死亡的药剂
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
EP4162929A1 (en) Composite formulation comprising sitagliptin and dapagliflozin and preparation method therefor
PATTANAIK STRATEGIES TO DEVELOP FIXED DOSE COMBINATION OF DRONEDARONE HCL AND RANOLAZINE EXTENDED RELEASE TABLETS USING QUALITY BY DESIGN
Neelamegarajan Formulation Design, Development and Invitro Evaluation of Fast Dissolving Tablets of Sitagliptin by Direct Compression Method
US20240122858A1 (en) Modified-release dosage forms of ruxolitinib

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201224